Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minozac Free Base SCHEMBL2799232 | 0.99 | TSHR (0.47) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| Minozac Free Base SCHEMBL29369390 | 0.99 | TSHR (0.47) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| Minozac Free Base SCHEMBL2394574 | 0.97 | TSHR (0.46) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL1753063 | 0.90 | CSNK1D (0.46) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL1752999 | 0.86 | MAPT (0.59) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL29295411 | 0.86 | DKK1 (0.48) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL720267 | 0.86 | SLC6A7 (0.56) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL29572108 | 0.86 | SLC6A7 (0.56) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL1752911 | 0.84 | HTT (0.51) | MAPTTSHRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL1753200 | 0.84 | MAPT (0.47) | MAPTTSHRLMNAKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168120-A1 | SALTS OF PYRIDAZINE COMPOUNDS | NEUROMEDIX INC. (CA) | 2010-07-01 | — | — | US | claimed |
| US-20090325973-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-31 | — | — | US | claimed |
| EP-2063894-A2 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | The Regents Of Northwestern University (US) | 2009-06-03 | — | — | EP | claimed |
| EP-2015751-A2 | SALTS OF PYRIDAZINE COMPOUNDS | Northwestern University (US) | 2009-01-21 | — | — | EP | claimed |
| WO-2007127375-A2 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | claimed |
| WO-2007127448-A2 | SALTS OF PYRIDAZINE COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | claimed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| US-20260008771-A1 | PYRIDAZINE BASED SMALL MOLECULE INHIBITOR OF COGNITIVE IMPAIRMENT | NORTHWESTERN UNIVERSITY | 2026-01-08 | — | — | US | disclosed |
| EP-4544544-A1 | DETECTING LONGITUDINAL PROGRESSION OF ALZHEIMER'S DISEASE (AD) BASED ON SPEECH ANALYSES | Genentech Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250107746-A1 | DETECTING LONGITUDINAL PROGRESSION OF ALZHEIMER'S DISEASE (AD) BASED ON SPEECH ANALYSES | GENENTECH INC (US) | 2025-04-03 | — | — | US | disclosed |
| CN-119404251-A | Detection of longitudinal progression of Alzheimer's Disease (AD) based on speech analysis | 基因泰克公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4494141-A1 | PREDICTING NEURODEGENERATIVE DISEASES BASED ON SPEECH ANALYSES | GENENTECH, INC. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20250000446-A1 | PREDICTING NEURODEGENERATIVE DISEASES BASED ON SPEECH ANALYSES | GENENTECH INC (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2007130383-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127475-A2 | PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127375-A2 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127474-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127448-A2 | SALTS OF PYRIDAZINE COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812408-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | Northwestern University (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050389-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008771-A1 | PYRIDAZINE BASED SMALL MOLECULE INHIBITOR OF COGNITIVE IMPAIRMENT | PSEN1, PSEN2, CHRNA6 | MAPT 6/4885TSHR 2020/4885LMNA 1338/4885 |
| US-20100168120-A1 | SALTS OF PYRIDAZINE COMPOUNDS | PTMS, TST, SRMS | MAPT 4354/4885TSHR 317/4885LMNA 3771/4885 |
| US-20090325973-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | TST, SRMS, STS | MAPT 3554/4885TSHR 3014/4885LMNA 2209/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | MAPT 56/4885TSHR 1976/4885LMNA 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.